Genzyme Announces Publication Of Study Showing Impact Of Cerezyme On Bone Health For Patients With Type 1 Gaucher Disease

... Genzyme Corporation (Nasdaq: GENZ) announced today that a research study published in the January issue of the Journal of Bone and Mineral Research demonstrates that long-term use of Cerezyme(R) (imiglucerase for injection) significantly improves bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner. [click link for full article] ...